President Donald Trump asserted that his administration's tariffs directly influenced Swiss pharmaceutical giant Novartis AG to expand its US-based manufacturing operations. This claim emerged during a meeting with Novartis CEO Vas Narasimhan at the White House on Wednesday. Trump stated the tariffs created a favorable environment, prompting Novartis to increase production within the United States.

The announcement carries significant weight in the ongoing debate over US manufacturing and the impact of trade policies on multinational corporations. Novartis cited the need to enhance supply chain resilience and meet growing domestic demand for critical medications as key drivers behind the expansion. The move underscores the complex interplay between international trade measures and corporate strategic decisions within the highly regulated drug industry. While the exact financial investment and timeline for the expansion were not disclosed, the decision signals a potential shift towards greater domestic production capacity for a major global player.

This development is closely watched by investors and policymakers as it reflects how tariffs can reshape corporate investment strategies in specific sectors.